Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kristin L. McNally is active.

Publication


Featured researches published by Kristin L. McNally.


Protein Engineering Design & Selection | 2009

Human variant Creutzfeldt-Jakob disease and sheep scrapie PrP(res) detection using seeded conversion of recombinant prion protein.

Christina D. Orrú; Jason M. Wilham; Andrew G. Hughson; Lynne D. Raymond; Kristin L. McNally; Alex Bossers; Ciriaco Ligios; Byron Caughey

The pathological isoform of the prion protein (PrP(res)) can serve as a marker for prion diseases, but more practical tests are needed for preclinical diagnosis and sensitive detection of many prion infections. Previously we showed that the quaking-induced conversion (QuIC) assay can detect sub-femtogram levels of PrP(res) in scrapie-infected hamster brain tissue and distinguish cerebral spinal fluid (CSF) samples from normal and scrapie-infected hamsters. We now report the adaptation of the QuIC reaction to prion diseases of medical and agricultural interest: human variant Creutzfeldt-Jakob disease (vCJD) and sheep scrapie. PrP(res)-positive and -negative brain homogenates from humans and sheep were discriminated within 1-2 days with a sensitivity of 10-100 fg PrP(res). More importantly, in as little as 22 h we were able to distinguish CSF samples from scrapie-infected and uninfected sheep. These results suggest the presence of prions in CSF from scrapie-infected sheep. This new method enables the relatively rapid and sensitive detection of human CJD and sheep scrapie PrP(res) and may facilitate the development of practical preclinical diagnostic and high-throughput interference tests.


Emerging Infectious Diseases | 2016

Nanopore Sequencing as a Rapidly Deployable Ebola Outbreak Tool

Thomas Hoenen; Allison Groseth; Kyle Rosenke; Robert J. Fischer; Andreas Hoenen; Seth Judson; Cynthia Martellaro; Darryl Falzarano; Andrea Marzi; R. Burke Squires; Kurt R. Wollenberg; Emmie de Wit; Joseph Prescott; David Safronetz; Trenton Bushmaker; Friederike Feldmann; Kristin L. McNally; Fatorma K. Bolay; Barry S. Fields; Tara K. Sealy; Mark Rayfield; Stuart T. Nichol; Kathryn C. Zoon; Moses Massaquoi; Vincent J. Munster; Heinz Feldmann

Rapid sequencing of RNA/DNA from pathogen samples obtained during disease outbreaks provides critical scientific and public health information. However, challenges exist for exporting samples to laboratories or establishing conventional sequencers in remote outbreak regions. We successfully used a novel, pocket-sized nanopore sequencer at a field diagnostic laboratory in Liberia during the current Ebola virus outbreak.


Journal of Virology | 2009

Cells Expressing Anchorless Prion Protein Are Resistant to Scrapie Infection

Kristin L. McNally; Anne Ward; Suzette A. Priola

ABSTRACT The hallmark of transmissible spongiform encephalopathies (TSEs or prion diseases) is the accumulation of an abnormally folded, partially protease-resistant form (PrP-res) of the normal protease-sensitive prion protein (PrP-sen). PrP-sen is attached to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor. In vitro, the anchor and the local membrane environment are important for the conversion of PrP-sen to PrP-res. In vivo, however, the anchor is not necessary because transgenic mice expressing anchorless PrP-sen accumulate PrP-res and replicate infectivity. To clarify the role of the GPI anchor in TSE infection, cells expressing GPI-anchored PrP-sen, anchorless PrP-sen, or both forms of PrP-sen were exposed to the mouse scrapie strain 22L. Cells expressing anchored PrP-sen produced PrP-res after exposure to 22L. Surprisingly, while cells expressing anchorless PrP-sen made anchorless PrP-res in the first 96 h postinfection, no PrP-res was detected at later passes. In contrast, when cells expressing both forms of PrP-sen were exposed to 22L, both anchored and anchorless PrP-res were detected over multiple passes. Consistent with the in vitro data, scrapie-infected cells expressing anchored PrP-sen transmitted disease to mice whereas cells expressing anchorless PrP-sen alone did not. These results demonstrate that the GPI anchor on PrP-sen is important for the persistent infection of cells in vitro. Our data suggest that cells expressing anchorless PrP-sen are not directly infected with scrapie. Thus, PrP-res formation in transgenic mice expressing anchorless PrP-sen may be occurring extracellularly.


Journal of Immunology | 2017

Adaptive Immune Responses to Zika Virus Are Important for Controlling Virus Infection and Preventing Infection in Brain and Testes

Clayton W. Winkler; Lara Myers; Tyson A. Woods; Ronald J. Messer; Aaron B. Carmody; Kristin L. McNally; Dana P. Scott; Kim J. Hasenkrug; Sonja M. Best; Karin E. Peterson

The recent association between Zika virus (ZIKV) and neurologic complications, including Guillain-Barré syndrome in adults and CNS abnormalities in fetuses, highlights the importance in understanding the immunological mechanisms controlling this emerging infection. Studies have indicated that ZIKV evades the human type I IFN response, suggesting a role for the adaptive immune response in resolving infection. However, the inability of ZIKV to antagonize the mouse IFN response renders the virus highly susceptible to circulating IFN in murine models. Thus, as we show in this article, although wild-type C57BL/6 mice mount cell-mediated and humoral adaptive immune responses to ZIKV, these responses were not required to prevent disease. However, when the type I IFN response of mice was suppressed, then the adaptive immune responses became critical. For example, when type I IFN signaling was blocked by Abs in Rag1−/− mice, the mice showed dramatic weight loss and ZIKV infection in the brain and testes. This phenotype was not observed in Ig-treated Rag1−/− mice or wild-type mice treated with anti–type I IFNR alone. Furthermore, we found that the CD8+ T cell responses of pregnant mice to ZIKV infection were diminished compared with nonpregnant mice. It is possible that diminished cell-mediated immunity during pregnancy could increase virus spread to the fetus. These results demonstrate an important role for the adaptive immune response in the control of ZIKV infection and imply that vaccination may prevent ZIKV-related disease, particularly when the type I IFN response is suppressed as it is in humans.


Prion | 2009

The role of the prion protein membrane anchor in prion infection

Suzette A. Priola; Kristin L. McNally

In transmissible spongiform encephalopathies (TSE or prion diseases) such as sheep scrapie, bovine spongiform encephalopathy and human Creutzfeldt-Jakob disease, normally soluble and protease-sensitive prion protein (PrP-sen or PrPC) is converted to an abnormal, insoluble and protease-resistant form termed PrP-res or PrPSc. PrP-res/PrPSc is believed to be the main component of the prion, the infectious agent of the TSE/prion diseases. Its precursor, PrP-sen, is anchored to the cell surface at the C-terminus by a co-translationally added glycophosphatidyl-inositol (GPI) membrane anchor which can be cleaved by the enzyme phosphatidyl-inositol specific phospholipase (PIPLC). The GPI anchor is also present in PrP-res, but is inaccessible to PIPLC digestion suggesting that conformational changes in PrP associated with PrP-res formation have blocked the PIPLC cleavage site. Although the GPI anchor is present in both PrP-sen and PrP-res, its precise role in TSE diseases remains unclear primarily because there are data to suggest that it both is and is not necessary for PrP-res formation and prion infection.


Clinical Infectious Diseases | 2016

Plasmodium Parasitemia Associated With Increased Survival in Ebola Virus–Infected Patients

Kyle Rosenke; Jennifer Adjemian; Vincent J. Munster; Andrea Marzi; Darryl Falzarano; Clayton O. Onyango; Melvin Ochieng; Bonventure Juma; Robert J. Fischer; Joseph Prescott; David Safronetz; Victor Omballa; Collins Owuor; Thomas Hoenen; Allison Groseth; Cynthia Martellaro; Galina E. Zemtsova; Joshua S. Self; Trenton Bushmaker; Kristin L. McNally; Thomas Rowe; Shannon L. Emery; Friederike Feldmann; Brandi N. Williamson; Sonja M. Best; Tolbert Nyenswah; Allen Grolla; James E. Strong; Gary P. Kobinger; Fatorma K. Bolay

BACKGROUND The ongoing Ebola outbreak in West Africa has resulted in 28 646 suspected, probable, and confirmed Ebola virus infections. Nevertheless, malaria remains a large public health burden in the region affected by the outbreak. A joint Centers for Disease Control and Prevention/National Institutes of Health diagnostic laboratory was established in Monrovia, Liberia, in August 2014, to provide laboratory diagnostics for Ebola virus. METHODS All blood samples from suspected Ebola virus-infected patients admitted to the Médecins Sans Frontières ELWA3 Ebola treatment unit in Monrovia were tested by quantitative real-time polymerase chain reaction for the presence of Ebola virus and Plasmodium species RNA. Clinical outcome in laboratory-confirmed Ebola virus-infected patients was analyzed as a function of age, sex, Ebola viremia, and Plasmodium species parasitemia. RESULTS The case fatality rate of 1182 patients with laboratory-confirmed Ebola virus infections was 52%. The probability of surviving decreased with increasing age and decreased with increasing Ebola viral load. Ebola virus-infected patients were 20% more likely to survive when Plasmodium species parasitemia was detected, even after controlling for Ebola viral load and age; those with the highest levels of parasitemia had a survival rate of 83%. This effect was independent of treatment with antimalarials, as this was provided to all patients. Moreover, treatment with antimalarials did not affect survival in the Ebola virus mouse model. CONCLUSIONS Plasmodium species parasitemia is associated with an increase in the probability of surviving Ebola virus infection. More research is needed to understand the molecular mechanism underlying this remarkable phenomenon and translate it into treatment options for Ebola virus infection.


Emerging Infectious Diseases | 2016

The Merits of Malaria Diagnostics during an Ebola Virus Disease Outbreak

Emmie de Wit; Darryl Falzarano; Clayton O. Onyango; Kyle Rosenke; Andrea Marzi; Melvin Ochieng; Bonventure Juma; Robert J. Fischer; Joseph Prescott; David Safronetz; Victor Omballa; Collins Owuor; Thomas Hoenen; Allison Groseth; Galina E. Zemtsova; Joshua S. Self; Trenton Bushmaker; Kristin L. McNally; Thomas Rowe; Shannon L. Emery; Friederike Feldmann; Brandi N. Williamson; Tolbert Nyenswah; Allen Grolla; James E. Strong; Gary P. Kobinger; Ute Stroeher; Mark Rayfield; Fatorma K. Bolay; Kathryn C. Zoon

Malaria is a major public health concern in the countries affected by the Ebola virus disease epidemic in West Africa. We determined the feasibility of using molecular malaria diagnostics during an Ebola virus disease outbreak and report the incidence of Plasmodium spp. parasitemia in persons with suspected Ebola virus infection.


PLOS ONE | 2017

Interferon signaling in Peromyscus leucopus confers a potent and specific restriction to vector-borne flaviviruses

Adaeze O. Izuogu; Kristin L. McNally; Stephen E. Harris; Brian H. Youseff; John B. Presloid; Christopher Burlak; Jason Munshi-South; Sonja M. Best; R. Travis Taylor

Tick-borne flaviviruses (TBFVs), including Powassan virus and tick-borne encephalitis virus cause encephalitis or hemorrhagic fevers in humans with case-fatality rates ranging from 1–30%. Despite severe disease in humans, TBFV infection of natural rodent hosts has little noticeable effect. Currently, the basis for resistance to disease is not known. We hypothesize that the coevolution of flaviviruses with their respective hosts has shaped the evolution of potent antiviral factors that suppress virus replication and protect the host from lethal infection. In the current study, we compared virus infection between reservoir host cells and related susceptible species. Infection of primary fibroblasts from the white-footed mouse (Peromyscus leucopus, a representative host) with a panel of vector-borne flaviviruses showed up to a 10,000-fold reduction in virus titer compared to control Mus musculus cells. Replication of vesicular stomatitis virus was equivalent in P. leucopus and M. musculus cells suggesting that restriction was flavivirus-specific. Step-wise comparison of the virus infection cycle revealed a significant block to viral RNA replication, but not virus entry, in P. leucopus cells. To understand the role of the type I interferon (IFN) response in virus restriction, we knocked down signal transducer and activator of transcription 1 (STAT1) or the type I IFN receptor (IFNAR1) by RNA interference. Loss of IFNAR1 or STAT1 significantly relieved the block in virus replication in P. leucopus cells. The major IFN antagonist encoded by TBFV, nonstructural protein 5, was functional in P. leucopus cells, thus ruling out ineffective viral antagonism of the host IFN response. Collectively, this work demonstrates that the IFN response of P. leucopus imparts a strong and virus-specific barrier to flavivirus replication. Future identification of the IFN-stimulated genes responsible for virus restriction specifically in P. leucopus will yield mechanistic insight into efficient control of virus replication and may inform the development of antiviral therapeutics.


Frontiers in Cellular and Infection Microbiology | 2018

Lethal Zika Virus Disease Models in Young and Older Interferon α/β Receptor Knock Out Mice

Andrea Marzi; Jackson Emanuel; Julie Callison; Kristin L. McNally; Nicolette Arndt; Spencer Chadinha; Cynthia Martellaro; Rebecca Rosenke; Dana P. Scott; David Safronetz; Stephen S. Whitehead; Sonja M. Best; Heinz Feldmann

The common small animal disease models for Zika virus (ZIKV) are mice lacking the interferon responses, but infection of interferon receptor α/β knock out (IFNAR−/−) mice is not uniformly lethal particularly in older animals. Here we sought to advance this model in regard to lethality for future countermeasure efficacy testing against more recent ZIKV strains from the Asian lineage, preferably the American sublineage. We first infected IFNAR−/− mice subcutaneously with the contemporary ZIKV-Paraiba strain resulting in predominantly neurological disease with ~50% lethality. Infection with ZIKV-Paraiba by different routes established a uniformly lethal model only in young mice (4-week old) upon intraperitoneal infection. However, intraperitoneal inoculation of ZIKV-French Polynesia resulted in uniform lethality in older IFNAR−/− mice (10–12-weeks old). In conclusion, we have established uniformly lethal mouse disease models for efficacy testing of antivirals and vaccines against recent ZIKV strains representing the Asian lineage.


Journal of Immunology | 2018

Cutting Edge: CCR2 Is Not Required for Ly6Chi Monocyte Egress from the Bone Marrow but Is Necessary for Migration within the Brain in La Crosse Virus Encephalitis

Clayton W. Winkler; Tyson A. Woods; Shelly J. Robertson; Kristin L. McNally; Aaron B. Carmody; Sonja M. Best; Karin E. Peterson

Inflammatory monocyte (iMO) recruitment to the brain is a hallmark of many neurologic diseases. Prior to entering the brain, iMOs must egress into the blood from the bone marrow through a mechanism, which for known encephalitic viruses, is CCR2 dependent. In this article, we show that during La Crosse Virus-induced encephalitis, egress of iMOs was surprisingly independent of CCR2, with similar percentages of iMOs in the blood and brain of heterozygous and CCR2−/− mice following infection. Interestingly, CCR2 was required for iMO trafficking from perivascular areas to sites of virus infection within the brain. Thus, CCR2 was not essential for iMO trafficking to the blood or the brain but was essential for trafficking within the brain parenchyma. Analysis of other orthobunyaviruses showed that Jamestown Canyon virus also induced CCR2-independent iMO egress to the blood. These studies demonstrate that the CCR2 requirement for iMO egress to the blood is not universal for all viruses.

Collaboration


Dive into the Kristin L. McNally's collaboration.

Top Co-Authors

Avatar

Sonja M. Best

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Andrea Marzi

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Allison Groseth

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Darryl Falzarano

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

David Safronetz

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Friederike Feldmann

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Joseph Prescott

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Kyle Rosenke

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Robert J. Fischer

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Thomas Hoenen

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge